KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Safety and Feasibility of Endoscopic-Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: An Exploratory Randomised Clinical Trial.

Loan Ngo-Stuyt, Rasmus Peuliche Vogelsang, Mustafa Bulut, Helle Hjorth Johannesen, Annika Loft, Malene Broholm, Mikail Gögenur, Adile Orhan, Michael Seiersen, Trine Stigaard, Julie Gehl, Ismail Gögenur

Cancers (Basel) 18(18) 3066

PMID42795032
PMCIDPMC13605616
DOI10.3390/cancers18183066
发表日期2026-09-26
入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要

摘要

BACKGROUND: Locally advanced rectal cancer (LARC) has high recurrence rates despite aggressive multimodal treatment with neoadjuvant chemoradiotherapy (CRT) followed by surgery. Electrochemotherapy (ECT), combining electroporation with chemotherapy, has shown safety and feasibility in other malignancies, but its role as an additive neoadjuvant treatment in rectal cancer remains unexplored. METHODS: In this parallel-group, randomised safety and feasibility trial, patients with histologically verified LARC who completed neoadjuvant CRT were randomised 1:1 to a single ECT treatment with bleomycin before surgery (n = 8) or standard therapy (n = 8). The primary outcome was safety (amended from the protocol-specified efficacy endpoint after early study termination). Follow-up was scheduled before surgery and at 6 and 12 weeks post-surgery, including adverse events, clinical examination, and patient-reported quality of life, bowel, urinary, and sexual function. RESULTS: ECT was successfully delivered in all treated patients. Median procedure time was 23.5 min. Adverse events occurred in all ECT patients, predominantly rectal pain (86%), with one patient hospitalised for pain management. No procedure-related complications were observed. Two ECT patients had R1 resections due to intraoperative perforations. Tumour response was heterogeneous: two patients achieved complete response (TRG1), three achieved partial response (TRG2-3), and one achieved no response; corresponding numbers in the control group were 2, 4, and 2. One ECT patient achieved clinical complete response and entered a watch-and-wait programme. Patient-reported pain worsened transiently after ECT but returned to baseline by 12 weeks post-surgery. CONCLUSIONS: ECT is a technically feasible adjunct to neoadjuvant CRT for LARC. However, its efficacy and safety, particularly regarding surgical complications, remain unclear. Larger trials are needed to determine the role of ECT in multimodal neoadjuvant treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。